Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Торасемид в лечении кардиоваскулярной патологии: оптимальное применение в условиях коморбидности - Журнал Системные Гипертензии Том 12, №4
Торасемид в лечении кардиоваскулярной патологии: оптимальное применение в условиях коморбидности
Потешкина Н.Г., Трошина А.А. Торасемид в лечении кардиоваскулярной патологии: оптимальное применение в условиях коморбидности. Системные гипертензии. 2015; 12 (4): 38–41.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Статья посвящена обзору современных клинических данных по применению одного из современных фармакологических препаратов – торасемида (Диувер, Teva Pharmaceutical Industries Ltd., Израиль) при лечении кардиоваскулярной патологии в условиях коморбидности. Представлен комплексный взгляд на проблему и определен аргументированный подход к выбору диуретической терапии с клинико-патофизиологическим обоснованием использования петлевого диуретика торасемид (Диувер). Концептуально сформирован ряд положений по применению одного из современных диуретических препаратов в терапевтической практике у пациентов с артериальной гипертензией и сердечной недостаточностью.
Ключевые слова: артериальная гипертензия, сердечная недостаточность, торасемид, Диувер.
Key words: hypertension, heart failure, torasemid, Diuver
Ключевые слова: артериальная гипертензия, сердечная недостаточность, торасемид, Диувер.
________________________________________________
Key words: hypertension, heart failure, torasemid, Diuver
Полный текст
Список литературы
1. Кардиоваскулярная терапия и профилактика. Национальные рекомендации. Разработаны Комитетом экспертов ВНОК, Москва, 2011. Кардиоваск. терапия и профилактика. 2011; 10 (6. Прил. 2): 3–64. / Kardiovaskuliarnaia terapiia i profilaktika. Natsional'nye rekomendatsii. Razrabotany Komitetom ekspertov VNOK, Moskva, 2011. Kardiovask. terapiia i profilaktika. 2011; 10 (6. Pril. 2): 3–64. [in Russian]
2. Mendis S et al. Global Atlas on cardiovascular disease prevention and control. Published by the World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization.World Health Organization, Geneva 2011.Available on the WHO web site (www.who.int). World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland.
3. Yancy CW, Jessup M, Bozkurt B et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62 (16): e147–e239.
4. McMurray JJV, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14 (8): 803–69.
5. Mozaffarian D, Benjamin EJ, Go AS et al. AHA Statistical Update Heart Disease and Stroke Statistics – 2015 Update A Report From the American Heart Association. Circulation 2015; 131: e29–e322. [in Russian]
6. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная недостаточность. 2013; 14 (7): 379–472. / Mareev V.Iu., Ageev F.T., Arutiunov G.P. i dr. Natsional'nye rekomendatsii OSSN, RKO i RNMOT po diagnostike i lecheniiu KhSN (chetvertyi peresmotr). Serdechnaia nedostatochnost'. 2013; 14 (7): 379–472. [in Russian]
7. Schocken DD, Benjamin EJ, Fonarow GC et al. Prevention of Heart Failure. A Scientific Statement From the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2008; 117: 2544–65.
8. Go AS, Mozaffarian D, Roger VL et al. AHA Statistical Update. Heart Disease and Stroke Statistics – 2013 Update. A Report From the American Heart Association. Circulation 2013; 127: e6–e245.
9. Appel LJ, Frohlich ED, Hall JE et al. AHA Presidential Advisory. The Importance of Population-Wide Sodium Reduction as a Means to Prevent Cardiovascular Disease and Stroke. A Call to Action From the American Heart Association. Circulation 2011; 123: 1138–43.
10. A global brief on Hypertension. Silent killer, global public health crisis. CWorld Health Organization 2013. Are available on the WHO web site (www.who.int) World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland. Document number: WHO/DCO/WHD/2013.2.
11. Prevention of Cardiovascular Disease Guidelines for assessment and management of cardiovascular risk. World Health Organization, 2007.
12. Национальные рекомендации по диагностике и лечению артериальной гипертонии РМОАГ/ВНОК. Кардиоваск. терапия и профилактика. 2008; 7 (6. Прил. 2). / Natsional'nye rekomendatsii po diagnostike i lecheniiu arterial'noi gipertonii RMOAG/VNOK. Kardiovask. terapiia i profilaktika. 2008; 7 (6. Pril. 2). [in Russian]
13. Российское медицинское общество по артериальной гипертонии (РМОАГ), Всероссийское научное общество кардиологов (ВНОК). Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии. 2010; 7 (3): 5–26. / Rossiiskoe meditsinskoe obshchestvo po arterial'noi gipertonii (RMOAG), Vserossiiskoe nauchnoe obshchestvo kardiologov (VNOK). Diagnostika i lechenie arterial'noi gipertenzii. Rossiiskie rekomendatsii (chetvertyi peresmotr). Systemic Hypertension. 2010; 7 (3): 5–26. [in Russian]
14. González A, Ravassa S, Beaumont J et al. New Targets to Treat the Structural Remodeling of the Myocardium. J Am Coll Cardiol 2011; 58 (18): 1833–43.
15. James PA et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311 (5): 507–20.
16. Перепеч Н.Б. Патогенетическая терапия хронической сердечной недостаточности: позиция торасемида. Системные гипертензии. 2015; 12 (3): 16–22. / Perepech N.B. Patogeneticheskaia terapiia khronicheskoi serdechnoi nedostatochnosti: pozitsiia torasemida. Systemic Hypertension. 2015; 12 (3): 16–22. [in Russian]
17. Mancia G et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159–219.
18. Потешкина Н.Г. Комбинированный препарат периндоприла и амлодипина в лечении артериальной гипертензии: эффективно, безопасно, оптимально. Consilium Medicum. 2014; 16 (5): 10–4. / Poteshkina N.G. Kombinirovannyi preparat perindoprila i amlodipina v lechenii arterial'noi gipertenzii: effektivno, bezopasno, optimal'no. Consilium Medicum. 2014; 16 (5): 10–4. [in Russian]
19. Карпов Ю.А. Торасемид: рекомендации для клинического применения при хронической сердечной недостаточности и артериальной гипертензии. РМЖ. 2014; 23: 1676–81. / Karpov Iu.A. Torasemid: rekomendatsii dlia klinicheskogo primeneniia pri khronicheskoi serdechnoi nedostatochnosti i arterial'noi gipertenzii. RMZh. 2014; 23: 1676–81. [in Russian]
20. Леонова М.В. Место диуретиков в терапии артериальной гипертонии: фокус на новый петлевой диуретик торасемид. Consilium Medicum. 2015; 17 (10): 42–6. / Leonova M.V. Mesto diuretikov v terapii arterial'noi gipertonii: fokus na novyi petlevoi diuretik torasemid. Consilium Medicum. 2015; 17 (10): 42–6. [in Russian]
21. Овчинников А.Г. Особенности применения петлевого диуретика торасемида у больных с компенсированной сердечной недостаточностью. Consilium Medicum. 2015; 17 (5): 26–32. / Ovchinnikov A.G. Osobennosti primeneniia petlevogo diuretika torasemida u bol'nykh s kompensirovannoi serdechnoi nedostatochnost'iu. Consilium Medicum. 2015; 17 (5): 26–32. [in Russian]
22. Lopez B, Gonzalez A, Beaumont J et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol 2007; 50: 859–67.
23. Lopez B, Querejeta R, Gonzalez A et al. Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension 2009; 53: 236–42.
24. Furberg C.D. Treatment of hypertension: a failing report card. Am J Hypertens 2009; 22: 1–2.
25. Laragh JH, Sealey JE. The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure. Am J Hypertens 2011; 24: 1164–80.
2. Mendis S et al. Global Atlas on cardiovascular disease prevention and control. Published by the World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization.World Health Organization, Geneva 2011.Available on the WHO web site (www.who.int). World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland.
3. Yancy CW, Jessup M, Bozkurt B et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62 (16): e147–e239.
4. McMurray JJV, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14 (8): 803–69.
5. Mozaffarian D, Benjamin EJ, Go AS et al. AHA Statistical Update Heart Disease and Stroke Statistics – 2015 Update A Report From the American Heart Association. Circulation 2015; 131: e29–e322. [in Russian]
6. Mareev V.Iu., Ageev F.T., Arutiunov G.P. i dr. Natsional'nye rekomendatsii OSSN, RKO i RNMOT po diagnostike i lecheniiu KhSN (chetvertyi peresmotr). Serdechnaia nedostatochnost'. 2013; 14 (7): 379–472. [in Russian]
7. Schocken DD, Benjamin EJ, Fonarow GC et al. Prevention of Heart Failure. A Scientific Statement From the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2008; 117: 2544–65.
8. Go AS, Mozaffarian D, Roger VL et al. AHA Statistical Update. Heart Disease and Stroke Statistics – 2013 Update. A Report From the American Heart Association. Circulation 2013; 127: e6–e245.
9. Appel LJ, Frohlich ED, Hall JE et al. AHA Presidential Advisory. The Importance of Population-Wide Sodium Reduction as a Means to Prevent Cardiovascular Disease and Stroke. A Call to Action From the American Heart Association. Circulation 2011; 123: 1138–43.
10. A global brief on Hypertension. Silent killer, global public health crisis. CWorld Health Organization 2013. Are available on the WHO web site (www.who.int) World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland. Document number: WHO/DCO/WHD/2013.2.
11. Prevention of Cardiovascular Disease Guidelines for assessment and management of cardiovascular risk. World Health Organization, 2007.
12. Natsional'nye rekomendatsii po diagnostike i lecheniiu arterial'noi gipertonii RMOAG/VNOK. Kardiovask. terapiia i profilaktika. 2008; 7 (6. Pril. 2). [in Russian]
13. Rossiiskoe meditsinskoe obshchestvo po arterial'noi gipertonii (RMOAG), Vserossiiskoe nauchnoe obshchestvo kardiologov (VNOK). Diagnostika i lechenie arterial'noi gipertenzii. Rossiiskie rekomendatsii (chetvertyi peresmotr). Systemic Hypertension. 2010; 7 (3): 5–26. [in Russian]
14. González A, Ravassa S, Beaumont J et al. New Targets to Treat the Structural Remodeling of the Myocardium. J Am Coll Cardiol 2011; 58 (18): 1833–43.
15. James PA et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311 (5): 507–20.
16. Perepech N.B. Patogeneticheskaia terapiia khronicheskoi serdechnoi nedostatochnosti: pozitsiia torasemida. Systemic Hypertension. 2015; 12 (3): 16–22. [in Russian]
17. Mancia G et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159–219.
18. Poteshkina N.G. Kombinirovannyi preparat perindoprila i amlodipina v lechenii arterial'noi gipertenzii: effektivno, bezopasno, optimal'no. Consilium Medicum. 2014; 16 (5): 10–4. [in Russian]
19. Karpov Iu.A. Torasemid: rekomendatsii dlia klinicheskogo primeneniia pri khronicheskoi serdechnoi nedostatochnosti i arterial'noi gipertenzii. RMZh. 2014; 23: 1676–81. [in Russian]
20. Leonova M.V. Mesto diuretikov v terapii arterial'noi gipertonii: fokus na novyi petlevoi diuretik torasemid. Consilium Medicum. 2015; 17 (10): 42–6. [in Russian]
21. Ovchinnikov A.G. Osobennosti primeneniia petlevogo diuretika torasemida u bol'nykh s kompensirovannoi serdechnoi nedostatochnost'iu. Consilium Medicum. 2015; 17 (5): 26–32. [in Russian]
22. Lopez B, Gonzalez A, Beaumont J et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol 2007; 50: 859–67.
23. Lopez B, Querejeta R, Gonzalez A et al. Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension 2009; 53: 236–42.
24. Furberg C.D. Treatment of hypertension: a failing report card. Am J Hypertens 2009; 22: 1–2.
25. Laragh JH, Sealey JE. The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure. Am J Hypertens 2011; 24: 1164–80.
2. Mendis S et al. Global Atlas on cardiovascular disease prevention and control. Published by the World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization.World Health Organization, Geneva 2011.Available on the WHO web site (www.who.int). World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland.
3. Yancy CW, Jessup M, Bozkurt B et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62 (16): e147–e239.
4. McMurray JJV, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14 (8): 803–69.
5. Mozaffarian D, Benjamin EJ, Go AS et al. AHA Statistical Update Heart Disease and Stroke Statistics – 2015 Update A Report From the American Heart Association. Circulation 2015; 131: e29–e322. [in Russian]
6. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная недостаточность. 2013; 14 (7): 379–472. / Mareev V.Iu., Ageev F.T., Arutiunov G.P. i dr. Natsional'nye rekomendatsii OSSN, RKO i RNMOT po diagnostike i lecheniiu KhSN (chetvertyi peresmotr). Serdechnaia nedostatochnost'. 2013; 14 (7): 379–472. [in Russian]
7. Schocken DD, Benjamin EJ, Fonarow GC et al. Prevention of Heart Failure. A Scientific Statement From the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2008; 117: 2544–65.
8. Go AS, Mozaffarian D, Roger VL et al. AHA Statistical Update. Heart Disease and Stroke Statistics – 2013 Update. A Report From the American Heart Association. Circulation 2013; 127: e6–e245.
9. Appel LJ, Frohlich ED, Hall JE et al. AHA Presidential Advisory. The Importance of Population-Wide Sodium Reduction as a Means to Prevent Cardiovascular Disease and Stroke. A Call to Action From the American Heart Association. Circulation 2011; 123: 1138–43.
10. A global brief on Hypertension. Silent killer, global public health crisis. CWorld Health Organization 2013. Are available on the WHO web site (www.who.int) World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland. Document number: WHO/DCO/WHD/2013.2.
11. Prevention of Cardiovascular Disease Guidelines for assessment and management of cardiovascular risk. World Health Organization, 2007.
12. Национальные рекомендации по диагностике и лечению артериальной гипертонии РМОАГ/ВНОК. Кардиоваск. терапия и профилактика. 2008; 7 (6. Прил. 2). / Natsional'nye rekomendatsii po diagnostike i lecheniiu arterial'noi gipertonii RMOAG/VNOK. Kardiovask. terapiia i profilaktika. 2008; 7 (6. Pril. 2). [in Russian]
13. Российское медицинское общество по артериальной гипертонии (РМОАГ), Всероссийское научное общество кардиологов (ВНОК). Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии. 2010; 7 (3): 5–26. / Rossiiskoe meditsinskoe obshchestvo po arterial'noi gipertonii (RMOAG), Vserossiiskoe nauchnoe obshchestvo kardiologov (VNOK). Diagnostika i lechenie arterial'noi gipertenzii. Rossiiskie rekomendatsii (chetvertyi peresmotr). Systemic Hypertension. 2010; 7 (3): 5–26. [in Russian]
14. González A, Ravassa S, Beaumont J et al. New Targets to Treat the Structural Remodeling of the Myocardium. J Am Coll Cardiol 2011; 58 (18): 1833–43.
15. James PA et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311 (5): 507–20.
16. Перепеч Н.Б. Патогенетическая терапия хронической сердечной недостаточности: позиция торасемида. Системные гипертензии. 2015; 12 (3): 16–22. / Perepech N.B. Patogeneticheskaia terapiia khronicheskoi serdechnoi nedostatochnosti: pozitsiia torasemida. Systemic Hypertension. 2015; 12 (3): 16–22. [in Russian]
17. Mancia G et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159–219.
18. Потешкина Н.Г. Комбинированный препарат периндоприла и амлодипина в лечении артериальной гипертензии: эффективно, безопасно, оптимально. Consilium Medicum. 2014; 16 (5): 10–4. / Poteshkina N.G. Kombinirovannyi preparat perindoprila i amlodipina v lechenii arterial'noi gipertenzii: effektivno, bezopasno, optimal'no. Consilium Medicum. 2014; 16 (5): 10–4. [in Russian]
19. Карпов Ю.А. Торасемид: рекомендации для клинического применения при хронической сердечной недостаточности и артериальной гипертензии. РМЖ. 2014; 23: 1676–81. / Karpov Iu.A. Torasemid: rekomendatsii dlia klinicheskogo primeneniia pri khronicheskoi serdechnoi nedostatochnosti i arterial'noi gipertenzii. RMZh. 2014; 23: 1676–81. [in Russian]
20. Леонова М.В. Место диуретиков в терапии артериальной гипертонии: фокус на новый петлевой диуретик торасемид. Consilium Medicum. 2015; 17 (10): 42–6. / Leonova M.V. Mesto diuretikov v terapii arterial'noi gipertonii: fokus na novyi petlevoi diuretik torasemid. Consilium Medicum. 2015; 17 (10): 42–6. [in Russian]
21. Овчинников А.Г. Особенности применения петлевого диуретика торасемида у больных с компенсированной сердечной недостаточностью. Consilium Medicum. 2015; 17 (5): 26–32. / Ovchinnikov A.G. Osobennosti primeneniia petlevogo diuretika torasemida u bol'nykh s kompensirovannoi serdechnoi nedostatochnost'iu. Consilium Medicum. 2015; 17 (5): 26–32. [in Russian]
22. Lopez B, Gonzalez A, Beaumont J et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol 2007; 50: 859–67.
23. Lopez B, Querejeta R, Gonzalez A et al. Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension 2009; 53: 236–42.
24. Furberg C.D. Treatment of hypertension: a failing report card. Am J Hypertens 2009; 22: 1–2.
25. Laragh JH, Sealey JE. The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure. Am J Hypertens 2011; 24: 1164–80.
________________________________________________
2. Mendis S et al. Global Atlas on cardiovascular disease prevention and control. Published by the World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization.World Health Organization, Geneva 2011.Available on the WHO web site (www.who.int). World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland.
3. Yancy CW, Jessup M, Bozkurt B et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62 (16): e147–e239.
4. McMurray JJV, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14 (8): 803–69.
5. Mozaffarian D, Benjamin EJ, Go AS et al. AHA Statistical Update Heart Disease and Stroke Statistics – 2015 Update A Report From the American Heart Association. Circulation 2015; 131: e29–e322. [in Russian]
6. Mareev V.Iu., Ageev F.T., Arutiunov G.P. i dr. Natsional'nye rekomendatsii OSSN, RKO i RNMOT po diagnostike i lecheniiu KhSN (chetvertyi peresmotr). Serdechnaia nedostatochnost'. 2013; 14 (7): 379–472. [in Russian]
7. Schocken DD, Benjamin EJ, Fonarow GC et al. Prevention of Heart Failure. A Scientific Statement From the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2008; 117: 2544–65.
8. Go AS, Mozaffarian D, Roger VL et al. AHA Statistical Update. Heart Disease and Stroke Statistics – 2013 Update. A Report From the American Heart Association. Circulation 2013; 127: e6–e245.
9. Appel LJ, Frohlich ED, Hall JE et al. AHA Presidential Advisory. The Importance of Population-Wide Sodium Reduction as a Means to Prevent Cardiovascular Disease and Stroke. A Call to Action From the American Heart Association. Circulation 2011; 123: 1138–43.
10. A global brief on Hypertension. Silent killer, global public health crisis. CWorld Health Organization 2013. Are available on the WHO web site (www.who.int) World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland. Document number: WHO/DCO/WHD/2013.2.
11. Prevention of Cardiovascular Disease Guidelines for assessment and management of cardiovascular risk. World Health Organization, 2007.
12. Natsional'nye rekomendatsii po diagnostike i lecheniiu arterial'noi gipertonii RMOAG/VNOK. Kardiovask. terapiia i profilaktika. 2008; 7 (6. Pril. 2). [in Russian]
13. Rossiiskoe meditsinskoe obshchestvo po arterial'noi gipertonii (RMOAG), Vserossiiskoe nauchnoe obshchestvo kardiologov (VNOK). Diagnostika i lechenie arterial'noi gipertenzii. Rossiiskie rekomendatsii (chetvertyi peresmotr). Systemic Hypertension. 2010; 7 (3): 5–26. [in Russian]
14. González A, Ravassa S, Beaumont J et al. New Targets to Treat the Structural Remodeling of the Myocardium. J Am Coll Cardiol 2011; 58 (18): 1833–43.
15. James PA et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311 (5): 507–20.
16. Perepech N.B. Patogeneticheskaia terapiia khronicheskoi serdechnoi nedostatochnosti: pozitsiia torasemida. Systemic Hypertension. 2015; 12 (3): 16–22. [in Russian]
17. Mancia G et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159–219.
18. Poteshkina N.G. Kombinirovannyi preparat perindoprila i amlodipina v lechenii arterial'noi gipertenzii: effektivno, bezopasno, optimal'no. Consilium Medicum. 2014; 16 (5): 10–4. [in Russian]
19. Karpov Iu.A. Torasemid: rekomendatsii dlia klinicheskogo primeneniia pri khronicheskoi serdechnoi nedostatochnosti i arterial'noi gipertenzii. RMZh. 2014; 23: 1676–81. [in Russian]
20. Leonova M.V. Mesto diuretikov v terapii arterial'noi gipertonii: fokus na novyi petlevoi diuretik torasemid. Consilium Medicum. 2015; 17 (10): 42–6. [in Russian]
21. Ovchinnikov A.G. Osobennosti primeneniia petlevogo diuretika torasemida u bol'nykh s kompensirovannoi serdechnoi nedostatochnost'iu. Consilium Medicum. 2015; 17 (5): 26–32. [in Russian]
22. Lopez B, Gonzalez A, Beaumont J et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol 2007; 50: 859–67.
23. Lopez B, Querejeta R, Gonzalez A et al. Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension 2009; 53: 236–42.
24. Furberg C.D. Treatment of hypertension: a failing report card. Am J Hypertens 2009; 22: 1–2.
25. Laragh JH, Sealey JE. The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure. Am J Hypertens 2011; 24: 1164–80.
Авторы
Н.Г.Потешкина*1, А.А.Трошина1,2
1 ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1;
2 ГБУЗ Городская клиническая больница №52 Департамента здравоохранения г. Москвы. 123182, Россия, Москва, ул. Пехотная, д. 3
*nat-pa@yandex.ru
1 N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1;
2 City Clinical Hospital №52 of the Department of Health of Moscow. 123182, Russian Federation, Moscow, ul. Pekhotnaia, d. 3
*nat-pa@yandex.ru
1 ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1;
2 ГБУЗ Городская клиническая больница №52 Департамента здравоохранения г. Москвы. 123182, Россия, Москва, ул. Пехотная, д. 3
*nat-pa@yandex.ru
________________________________________________
1 N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1;
2 City Clinical Hospital №52 of the Department of Health of Moscow. 123182, Russian Federation, Moscow, ul. Pekhotnaia, d. 3
*nat-pa@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.